These Are the Big Funds That Were Slammed in Biotech's Rout

Updated on
  • Diversified funds heavy in biotech down 3.8% since rout began
  • Fidelity, JPMorgan funds show recent losses on paper

It’s not just biotechnology specialists who have been hit by the slide in drug stocks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.